BioVie Inc (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for liver disease and neurological disorders, closed a public offering of 15M common shares, 6M pre-funded warrants, and warrants for 10.5M common shares at $1.00 each. With gross proceeds of approximately $21M, the company plans to utilize the funds for working capital and general corporate purposes.
The Markets by Proactive
Go to Proactive Australia
Proactive’s Australian coverage continues on .com